Search results for "Alanine Transaminase"

showing 10 items of 105 documents

An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers

2018

Background & Aims Interventions aimed at lifestyle changes are pivotal for the treatment of non-alcoholic fatty liver disease (NAFLD), and web-based programs might help remove barriers in both patients and therapists. Methods In the period 2010–15, 716 consecutive NAFLD cases (mean age, 52; type 2 diabetes, 33%) were treated in our Department with structured programs. The usual protocol included motivational interviewing and a group-based intervention (GBI), chaired by physicians, dietitians and psychologists (five weekly meetings, n = 438). Individuals who could not attend GBI entered a web-based intervention (WBI, n = 278) derived from GBI, with interactive games, learning tests, motivati…

Liver CirrhosisMalemedicine.medical_specialtyMotivational interviewingPsychological interventionType 2 diabetesDisease03 medical and health sciences0302 clinical medicinePatient Education as TopicWeight lossNon-alcoholic Fatty Liver DiseaseInternal medicineWeight LossmedicineHumansNAFLD progression030212 general & internal medicineExerciseLife StyleAged2. Zero hungerInternetHepatologybusiness.industryPhysical activityFatty liverLiver enzymeAlanine TransaminaseHepatologyMiddle Agedmedicine.diseaseDiet; Liver enzymes; NAFLD progression; Physical activity; HepatologyTelemedicineLiver enzymes3. Good healthDietLogistic Models030211 gastroenterology & hepatologyFemalemedicine.symptombusinessBody mass indexBiomarkers
researchProduct

Prevalence, predictors, and severity of lean nonalcoholic fatty liver disease in patients living with human immunodeficiency virus

2020

Abstract Background The burden of nonalcoholic fatty liver disease (NAFLD) is growing in people living with human immunodeficiency virus (HIV). NAFLD is associated with obesity; however, it can occur in normoweight (lean) patients. We aimed to investigate lean NAFLD in patients living with HIV. Methods We included patients living with HIV mono-infection from 3 prospective cohorts. NAFLD was diagnosed by transient elastography (TE) and defined as controlled attenuation parameter ≥248 dB/m, in absence of alcohol abuse. Lean NAFLD was defined when a body mass index was <25 kg/m2. Significant liver fibrosis was defined as TE ≥7.1 kPa. The presence of diabetes, hypertension, or hyperlipid…

Liver CirrhosisMicrobiology (medical)medicine.medical_specialtyTransient elastographyHIV InfectionsGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineDiabetes mellitusHyperlipidemiaNonalcoholic fatty liver diseasePrevalencemedicineHumansProspective Studies030212 general & internal medicineAgedbiologybusiness.industryHIVnutritional and metabolic diseasesLiver fibrosimedicine.diseasedigestive system diseasesInfectious DiseasesAlanine transaminaseDyslipidemiaalanine aminotransferase; controlled attenuation parameter; dyslipidemia; liver fibrosis; transient elastographyCohortControlled attenuation parameterbiology.proteinAlanine aminotransferase030211 gastroenterology & hepatologybusinessTransient elastographyBody mass indexDyslipidemia
researchProduct

Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts.

2012

A disseminated model of non-Hodgkin's lymphoma with prevalent liver metastasis was generated by intraperitoneal (i.p.) injection of EBV(+) B lymphoblastoid SKW6.4 in nude-SCID mice. The survival of SKW6.4 xenografts (median survival = 27 days) was significantly improved when hyaluronan scaffolds embedded with mesenchimal stem cells (MSC) were implanted in the abdominal area 4 days after SKW6.4 injection (median survival = 39.5 days). Mice implanted with MSC showed a significant improvement of hepatic functionality in lymphoma xenografts, as demonstrated by measurement of serum ALT/AST levels. Co-culture of MSC with lymphoma cells enhanced the release of hepatocyte growth factor (HGF) by MSC…

Liver functionality. Lymphoma-bearing xenograftsPathologymedicine.medical_specialtyTime FactorsCell SurvivalMice NudeCell CommunicationMice SCIDMesenchymal Stem Cell Transplantationlymphoma.Mesenchymal stem cells; hepato-protective; lymphoma.Metastasischemistry.chemical_compoundMicehemic and lymphatic diseasesCell Line Tumorhepato-protectiveHyaluronic acidMedicineAnimalsHumansPharmacology (medical)Aspartate AminotransferasesHyaluronic AcidMesenchymal stem cellPharmacologyMesenchymal stem cells; Liver functionality. Lymphoma-bearing xenograftsTissue Scaffoldsbusiness.industryHepatocyte Growth FactorLymphoblastLymphoma Non-HodgkinMesenchymal stem cellLiver NeoplasmsAlanine TransaminaseMesenchymal Stem Cellsmedicine.diseaseXenograft Model Antitumor AssaysCoculture TechniquesLymphomaOncologychemistryLiverCell cultureHepatocyte growth factorStem cellbusinessBiomarkersmedicine.drugInvestigational new drugs
researchProduct

Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19

2021

Abstract Objective The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19. Methods We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated. Results Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3–2.95 vs median, 0.82 nmol/L; interquartile range, 0.57–1.03; …

Lung DiseasesMalemedicine.medical_specialtySciencemedicine.medical_treatmentMR-proADMClinical BiochemistryComorbidityLabmed/1010Severity of Illness IndexGastroenterologyAdrenomedullinInterquartile rangeInternal medicineSeverity of illnessmedicineHumansAspartate AminotransferasesProtein PrecursorsSurvival analysisAgedRetrospective StudiesMechanical ventilationReceiver operating characteristicbiologyInterleukin-6SARS-CoV-2business.industryPatient SelectionBiochemistry (medical)C-reactive proteinCOVID-19Alanine TransaminaseRetrospective cohort studyMiddle AgedPrognosisSurvival Analysisrespiratory diseaseC-Reactive ProteininflammationHypertensionbiology.proteinbiomarkerBiomarker (medicine)FemaleTriagebusinessBiomarkersAcademicSubjects/MED00690Laboratory Medicine
researchProduct

Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.

2014

BACKGROUND This large prospective multicentre cohort study aimed to improve knowledge of therapy for chronic hepatitis C (CHC) in real clinical practice. METHODS A diverse population of adults with CHC including patients with comorbid conditions, laboratory abnormalities and demographic features [comorbidities or special populations (CSP)] who were under-represented or excluded from peginterferon registration studies was treated with peginterferon α-2a (40 kDa) or α-2b (12 kDa) plus ribavirin at the investigator's discretion. RESULTS During the study, 5399 treatment-naive patients [2527 (46.8%) with CSP] received peginterferon α-2a (n=3513, 65.1%) or peginterferon α-2b (n=1886, 34.9%). The …

MaleCirrhosisTime FactorsComorbidityHepacivirusmedicine.disease_causePolyethylene Glycolschemistry.chemical_compoundRecurrencepeginterferonProspective Studiesspecial populationAged 80 and overbiologyRemission InductionGastroenterologyvirus diseasesMiddle AgedViral LoadRecombinant ProteinsTreatment OutcomeItalyHCVRNA ViralDrug Therapy CombinationFemalesustained virological responseCohort studyAdultcomorbiditiemedicine.medical_specialtyAdolescentGenotypeHepatitis C virusInterferon alpha-2Antiviral AgentsYoung AdultChronic hepatitisInternal medicineRibavirinmedicineHumansIn patientMedical prescriptionAgedHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseasechemistryAlanine transaminaseImmunologybiology.proteinbusinessEuropean journal of gastroenterologyhepatology
researchProduct

Distribution and induction of cytochrome P-450 and two cytochrome P-450-dependent monooxygenase activities in rat liver parenchymal cell subpopulatio…

1989

Liver parenchymal cells from the periportal and centrilobular zones differ in their morphological, biochemical and functional characteristics. In an effort to obtain fractions enriched in either periportal or centrilobular cells, isolated rat liver parenchymal cells were separated into five subpopulations by centrifugal elutriation. The mean diameters of the cells present in fractions I-V were 19.6, 21.1, 21.8, 22.7 and 23.5 micron, respectively. The content of cytochrome P-450 as well as benzphetamine N-demethylase and 7-ethoxyresorufin O-deethylase activities were higher in the larger parenchymal cells than in the smaller ones. After administration of phenobarbital the content of cytochro…

MaleCytochromeHealth Toxicology and MutagenesisPyruvate KinaseElutriationIn Vitro TechniquesToxicologyMixed Function OxygenasesCytochrome P-450 Enzyme SystemParenchymamedicineCytochrome P-450 CYP1A1AnimalsEnzyme inducerbiologyCytochrome P450Alanine TransaminaseOxidoreductases N-DemethylatingRats Inbred StrainsGeneral MedicineMonooxygenaseRatsBiochemistryLiverEnzyme InductionPhenobarbitalbiology.proteinPhenobarbitalBenzphetamineOxidoreductasesmedicine.drugMethylcholanthreneArchives of toxicology
researchProduct

Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis

2012

Abstract Background Nonalcoholic fatty liver disease is a chronic metabolic disorder with significant impact on cardiovascular and liver mortality. Aims In this study, we examined the effects of silibinin on liver and myocardium injury in an experimental model of nonalcoholic fatty liver disease. Methods A four-week daily dose of silibinin (20 mg/kg i.p.) was administrated to db/db mice fed a methionine–choline deficient diet. Hepatic and myocardial histology, oxidative stress and inflammatory cytokines were evaluated. Results Silibinin administration decreased HOMA-IR, serum ALT and markedly improved hepatic and myocardial damage. Silibinin reduced isoprostanes, 8-deoxyguanosine and nitrit…

MaleGene ExpressionIsoprostanesmedicine.disease_causeGastroenterologyAntioxidantsMicechemistry.chemical_compoundMethionineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasePhosphorylationGastroenterologyAlanine TransaminaseGlutathioneCholine DeficiencyMitochondrial respiratory chainLiverHeart Inflammation NAFLD Oxidative stress SilibininCytokinesmedicine.symptomSilymarinmedicine.medical_specialtySilibininInflammationStatistics NonparametricProinflammatory cytokineInsulin resistanceInternal medicinemedicineAnimalsNitritesAnalysis of VarianceNitratesHepatologySettore BIO/16 - Anatomia Umanabusiness.industryMyocardiumJNK Mitogen-Activated Protein KinasesGlutathionemedicine.diseaseDietFatty LiverOxidative StressEndocrinologychemistrySilybinInsulin ResistancebusinessOxidative stressDigestive and Liver Disease
researchProduct

Improved nitrogen metabolism in rats fed on lipid-rich liquid diets

1994

N metabolism was studied in young rats fed on lipid-rich, isonitrogenous, purified liquid diets, a convenient and easy technique for inducing voluntary overfeeding of energy and lipids under controlled nutritional conditions. Overfed rats showed a marked N retention at the expense of a reduced production of urea. The capacities of isolated hepatocytes to synthesize urea and glucose from added precursors were greatly diminished. The activities of the urea cycle enzymes and several enzymes involved in the availability of NH3, for this pathway were concomitantly reduced in overfed animals. Therefore, our results showed an improved N metabolism in overfed rats promoted by the overfeeding of lip…

MaleLiquid dietNitrogenCarbamoyl-Phosphate Synthase (Ammonia)Medicine (miscellaneous)HyperphagiaBiologychemistry.chemical_compoundGlutamate DehydrogenaseAnimalsUreaAmino AcidsRats WistarNitrogen cycleCells Culturedchemistry.chemical_classificationNutrition and DieteticsCatabolismAlanine TransaminaseMetabolismLipidsDietRatsAmino acidGlucoseEnzymeLiverchemistryBiochemistryUrea cycleUreaBritish Journal of Nutrition
researchProduct

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis

2017

OBJECTIVES Non-invasive fibrosis scores are widely used to identify/exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). However, these scores were principally developed and validated in patients aged between 35 and 65 years of age. The objective of this study was to assess the effect of age on the performance of non-invasive fibrosis tests in NAFLD. METHODS Patients were recruited from European specialist hepatology clinics. The cohort was divided into five age-based groups: ≤35 (n=74), 36-45 (n=96), 46-55 (n=197), 56-64 (n=191), and ≥65 years (n=76), and the performance of the aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio, fibrosis 4 (F…

MaleLiver CirrhosisPathologyBiopsyPredictive Value of TestAspartate AminotransferasesGastroenterology0302 clinical medicineFibrosisReference ValuesNon-alcoholic Fatty Liver DiseaseArea under curvePrevalenceMedicineReference ValueAge FactorConfoundingAge FactorsGastroenterologyAlanine TransaminaseFalse Positive ReactionMiddle Aged3. Good healthLiver030220 oncology & carcinogenesisPredictive value of testsArea Under Curve030211 gastroenterology & hepatologyFemaleLiver pathologyHumanAdultmedicine.medical_specialtyLiver Cirrhosi610 Medicine & healthdigestive system03 medical and health sciencesPredictive Value of TestsInternal medicineHumansFalse Positive ReactionsAspartate AminotransferasesAgedHepatologybusiness.industryPlatelet CountNon invasivenutritional and metabolic diseasesAspartate AminotransferaseHepatologymedicine.diseaseFibrosisdigestive system diseasesFatty LiverROC CurveHuman medicinebusinessBiomarkersThe American Journal of Gastroenterology
researchProduct

Patterns of liver injury in COVID-19 - a German case series.

2020

BACKGROUND: Reports of liver injury in patients with novel coronavirus disease 2019 (COVID-19) are emerging from China and the USA. A wide variety of liver function test abnormalities and few cases of severe liver failure have been reported. No data on the hepatic phenotype from Europe are available at current. METHODS: We report a case series of 44 consecutive patients hospitalized for COVID-19 in Germany. RESULTS: At the time of admission, aspartate aminotransferase greater than the upper limit of normal was present in 70%, while alanine aminotransferase was elevated in 15.8%. Markers of cholestatic liver injury were altered only in a minority of patients. During hospitalization, 31% and …

MalePathologyGerman0302 clinical medicineCOVID-19 TestingLiver Function TestsGermanyMedicineElectronic Health RecordsYoung adultLiver injuryAged 80 and overmedicine.diagnostic_testbiologyGastroenterologyAlanine TransaminaseMiddle AgedOncologyLiver030220 oncology & carcinogenesislanguage030211 gastroenterology & hepatologyFemaleChemical and Drug Induced Liver InjuryCoronavirus InfectionsAdultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Pneumonia ViralAntiviral Agents03 medical and health sciencesBetacoronavirusYoung AdultInternal medicineHumansAspartate AminotransferasesPandemicsAgedRetrospective Studiesbusiness.industryClinical Laboratory TechniquesSARS-CoV-2COVID-19Retrospective cohort studyOriginal ArticlesHepatologyLiver Failure Acutemedicine.diseaselanguage.human_languageCOVID-19 Drug TreatmentAlanine transaminasebiology.proteinbusinessLiver function testsBiomarkersUnited European gastroenterology journal
researchProduct